Tocqueville Asset Management L.P. bought a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 214,510 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,958,000. Tocqueville Asset Management L.P. owned 0.61% of AMAG Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMAG. BlackRock Inc. raised its position in AMAG Pharmaceuticals by 67,790.9% during the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after acquiring an additional 4,988,054 shares during the period. Vanguard Group Inc. grew its holdings in shares of AMAG Pharmaceuticals by 6.1% during the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after buying an additional 176,832 shares in the last quarter. State Street Corp grew its holdings in shares of AMAG Pharmaceuticals by 10.6% during the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after buying an additional 267,873 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of AMAG Pharmaceuticals by 18.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares in the last quarter. Finally, Gotham Asset Management LLC grew its holdings in shares of AMAG Pharmaceuticals by 17.8% during the second quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock worth $14,721,000 after buying an additional 121,137 shares in the last quarter.

WARNING: “Tocqueville Asset Management L.P. Buys New Position in AMAG Pharmaceuticals, Inc. (AMAG)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/tocqueville-asset-management-l-p-buys-new-position-in-amag-pharmaceuticals-inc-amag/1682956.html.

AMAG has been the subject of a number of research reports. Piper Jaffray Companies initiated coverage on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $18.00 target price for the company. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a report on Tuesday, July 11th. Morgan Stanley started coverage on shares of AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective for the company. Deutsche Bank AG reissued a “hold” rating and issued a $24.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Finally, ValuEngine raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $25.50.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at $14.03 on Monday. AMAG Pharmaceuticals, Inc. has a one year low of $11.93 and a one year high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. The firm’s revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.45 earnings per share. research analysts forecast that AMAG Pharmaceuticals, Inc. will post -1.26 EPS for the current year.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.